Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$23.0 - $31.04 $24 Million - $32.4 Million
-1,042,458 Reduced 74.65%
353,961 $8.97 Million
Q1 2024

May 15, 2024

BUY
$27.35 - $40.45 $7.94 Million - $11.7 Million
290,430 Added 26.26%
1,396,419 $43.2 Million
Q4 2023

Feb 14, 2024

SELL
$24.02 - $43.89 $3.45 Million - $6.31 Million
-143,669 Reduced 11.5%
1,105,989 $44.6 Million
Q3 2023

Nov 14, 2023

BUY
$16.89 - $35.01 $13 Million - $27 Million
770,207 Added 160.64%
1,249,658 $33 Million
Q2 2023

Aug 14, 2023

SELL
$13.29 - $18.01 $7.48 Million - $10.1 Million
-563,035 Reduced 54.01%
479,451 $8.25 Million
Q1 2023

May 15, 2023

BUY
$7.17 - $18.55 $2.95 Million - $7.64 Million
411,775 Added 65.29%
1,042,486 $17.3 Million
Q4 2022

Feb 14, 2023

SELL
$6.74 - $11.52 $1.28 Million - $2.19 Million
-190,350 Reduced 23.18%
630,711 $4.81 Million
Q3 2022

Nov 14, 2022

BUY
$7.94 - $12.36 $5.8 Million - $9.03 Million
730,510 Added 806.74%
821,061 $8.16 Million
Q2 2022

Aug 15, 2022

SELL
$5.21 - $12.14 $1.83 Million - $4.27 Million
-351,412 Reduced 79.51%
90,551 $822,000
Q1 2022

May 16, 2022

BUY
$7.34 - $17.16 $1.52 Million - $3.54 Million
206,545 Added 87.74%
441,963 $4.49 Million
Q4 2021

Feb 14, 2022

BUY
$11.38 - $53.41 $2.68 Million - $12.6 Million
235,418 New
235,418 $3.93 Million
Q1 2021

May 17, 2021

SELL
$55.47 - $72.35 $6.6 Million - $8.61 Million
-119,021 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$38.38 - $71.11 $1.34 Million - $2.48 Million
-34,854 Reduced 22.65%
119,021 $8.46 Million
Q3 2020

Nov 16, 2020

BUY
$27.2 - $42.19 $2.61 Million - $4.05 Million
95,934 Added 165.57%
153,875 $5.77 Million
Q2 2020

Aug 14, 2020

BUY
$22.22 - $35.69 $1.29 Million - $2.07 Million
57,941 New
57,941 $1.89 Million

Others Institutions Holding BBIO

About BridgeBio Pharma, Inc.


  • Ticker BBIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 148,246,000
  • Market Cap $3.42B
  • Description
  • BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...
More about BBIO
Track This Portfolio

Track Voloridge Investment Management, LLC Portfolio

Follow Voloridge Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voloridge Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voloridge Investment Management, LLC with notifications on news.